News Channels

02 Aug 2017 Takeda and Cardurion Pharmaceuticals Launch Cardiovascular Development Partnership
02 Aug 2017 Madison Vaccines Announces First Patient Dosed in an Expanded Combination Trial of MVI-816 Plus Keytruda® for Metastatic, Treatment-Resistant Prostate Cancer
02 Aug 2017 Spark Therapeutics Submits Marketing Authorization Application to European Medicines Agency for Investigational LUXTURNA™ (voretigene neparvovec)
02 Aug 2017 BioCryst Announces Initiation of ZENITH-1, a Clinical Trial to Evaluate BCX7353 as an Acute Treatment of Hereditary Angioedema Attacks
02 Aug 2017 US FDA accepts regulatory submission for acalabrutinib and grants Priority Review
02 Aug 2017 CTI BioPharma Announces Completion of Enrollment in the Phase 3 PIX306 Trial of PIXUVRI® for Aggressive B-cell non-Hodgkin lymphoma
02 Aug 2017 Aprea Therapeutics Announces First Patient Enrolled in Phase Ib/II Clinical Study of APR-246 for the Treatment of Platinum-Resistant High-Grade Serous Ovarian Cancer
02 Aug 2017 U.S. FDA Approves Expanded Labeling for Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of Chronic Hepatitis C in Patients Co-Infected with HIV
01 Aug 2017 Aptinyx Initiates Phase 2 Clinical Studies Evaluating NYX-2925 in Two Chronic Pain Conditions
01 Aug 2017 Amygdala Neurosciences Initiates Phase 1b Clinical Study of ANS-6637, the First-In-Class Selective ALDH2 Inhibitor in Development as a Treatment for Substance Use Disorder
01 Aug 2017 Madrigal Pharmaceuticals Completes Enrollment in Phase 2 Proof-of-Concept Study with MGL-3196 for Treatment of NASH
01 Aug 2017 Cellectar Biosciences Signs Collaboration with Avicenna Oncology to Develop New PDCs for Solid Tumors
01 Aug 2017 Flex Pharma Initiates ALS Phase 2 Trial with FLX-787 in US
01 Aug 2017 Cycle Pharmaceuticals Receives FDA Approval of NityrTM (nitisinone) Tablets for Treatment of HT-1
01 Aug 2017 FDA Approves KALYDECO(R) (ivacaftor) for More Than 600 People Ages 2 and Older With Cystic Fibrosis Who Have Certain Residual Function Mutations
01 Aug 2017 uniQure Reacquires Development and Commercialization Rights for its Gene Therapy Candidate in Hemophilia B
01 Aug 2017 FDA Grants Approval of IDHIFA®, the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation
01 Aug 2017 Glenmark Pharmaceuticals Reports Positive Data in a Phase 2a Study of GBR 830 for the Treatment of Patients with Atopic Dermatitis
01 Aug 2017 Kitov Submits New Drug Application to FDA for KIT-302
01 Aug 2017 First Human Subject Enrolled in Lumosa Therapeutics' Phase 1 Trial for LT3001, a New Drug Molecule for Acute Ischemic Stroke

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top